Astrazeneca Will Manufacture Traditional Chinese Medicines

25 April 2022 Kuwait

According to local Chinese officials, AstraZeneca, a multinational pharmaceutical company, plans to establish an innovation centre for the development of traditional Chinese medicine pharmaceuticals in southwest China's Sichuan Province.

According to a local Arabic newspaper, the firm has inked an online agreement with Chengdu's high-tech industrial development zone to jointly build the centre, which will incubate and position the contemporary traditional Chinese medicine sector.

The centre includes a research institution run by academics as well as platforms that assist the TCM sector, business modernization, and clinical marketing. In November 2020, AstraZeneca opened its western China headquarters in Chengdu's high-tech industrial development zone, and the company's regional headquarters opened in September of the previous year.

More than 3,000 medical facilities may be found in Chengdu's high-tech industrial development zone. In the first quarter of 2022, significant medical and healthcare enterprises in the region raised their industrial output and industrial value-added by 14.2 percent and 8%, respectively, compared to the same period the previous year.

: 293

Comments Post Comment

Leave a Comment